These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37644514)

  • 21. [Clinical features and outcomes in relapsing and monophasic patients with anti-leucine-rich glioma-inactivated 1 encephalitis].
    Li JM; Ma XR; Peng T; Li JH; Lu H
    Zhonghua Yi Xue Za Zhi; 2020 Jul; 100(25):1947-1951. PubMed ID: 32629594
    [No Abstract]   [Full Text] [Related]  

  • 22. [Clinical analysis of 9 cases with Anti-leucine-rich glioma inactivated 1 protein antibody associated limbic encephalitis].
    Zhang YX; Yang HL; Wu YY; Wang CC; Gao XY; Shi YY; Liu HQ; Huang Y; Zhang JW
    Zhonghua Yi Xue Za Zhi; 2017 May; 97(17):1295-1298. PubMed ID: 28482428
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical characteristics of Leucine-rich glioma-inactivated protein 1 antibody-mediated autoimmune encephalitis in a 6-year-old girl: case report and literature reviews.
    Chen L; Su T; Liu Y
    BMC Neurol; 2023 Jun; 23(1):253. PubMed ID: 37391712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A rare case of anti-LGI1 limbic encephalitis with concomitant positive NMDAR antibodies.
    Ji T; Huang Z; Lian Y; Wang C; Zhang Q; Li J
    BMC Neurol; 2020 Sep; 20(1):336. PubMed ID: 32894089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CSF Findings in Acute NMDAR and LGI1 Antibody-Associated Autoimmune Encephalitis.
    Dürr M; Nissen G; Sühs KW; Schwenkenbecher P; Geis C; Ringelstein M; Hartung HP; Friese MA; Kaufmann M; Malter MP; Madlener M; Thaler FS; Kümpfel T; Senel M; Häusler MG; Schneider H; Bergh FT; Kellinghaus C; Zettl UK; Wandinger KP; Melzer N; Gross CC; Lange P; Dreyhaupt J; Tumani H; Leypoldt F; Lewerenz J;
    Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34697224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytokines/chemokines and soluble immune checkpoint molecules in anti-GABA
    Qiao S; Xie Y; Li H; Zhang R; Wu Y; Liu X; Zhang S
    Mult Scler Relat Disord; 2022 Dec; 68():104234. PubMed ID: 36270252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The diagnosis of anti-LGI1 encephalitis varies with the type of immunodetection assay and sample examined.
    Muñoz-Sánchez G; Planagumà J; Naranjo L; Couso R; Sabater L; Guasp M; Martínez-Hernández E; Graus F; Dalmau J; Ruiz-García R
    Front Immunol; 2022; 13():1069368. PubMed ID: 36591253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-LGI1 Encephalitis Developing Immunoglobulin Responsive Orthostatic Hypotension after Remission.
    Orimo K; Iwata NK; Kawai M; Nakajima H; Takeda K; Murai H; Goto J
    Intern Med; 2021 Sep; 60(18):3021-3024. PubMed ID: 33055478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical characteristics and short-term prognosis of LGI1 antibody encephalitis: a retrospective case study.
    Li W; Wu S; Meng Q; Zhang X; Guo Y; Cong L; Cong S; Zheng D
    BMC Neurol; 2018 Jul; 18(1):96. PubMed ID: 29980179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Features and Therapeutic Effects of Anti-leucine-rich Glioma Inactivated 1 Encephalitis: A Systematic Review.
    Teng Y; Li T; Yang Z; Su M; Ni J; Wei M; Shi J; Tian J
    Front Neurol; 2021; 12():791014. PubMed ID: 35095736
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical and Prognostic Value of Immunogenetic Characteristics in Anti-LGI1 Encephalitis.
    Muñiz-Castrillo S; Haesebaert J; Thomas L; Vogrig A; Pinto AL; Picard G; Blanc C; Do LD; Joubert B; Berzero G; Psimaras D; Alentorn A; Rogemond V; Dubois V; Ambati A; Tamouza R; Mignot E; Honnorat J
    Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33848259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody Properties Associate with Clinical Phenotype in LGI1 Encephalitis.
    Ludewig S; Salzburger L; Goihl A; Rohne J; Leypoldt F; Bittner D; Düzel E; Schraven B; Reinhold D; Korte M; Körtvélyessy P
    Cells; 2023 Jan; 12(2):. PubMed ID: 36672216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance and extra-hypothalamus dysfunction of hyponatremia in anti-leucine-rich glioma-inactivated protein 1 encephalitis.
    Liu X; Li G; Yu T; Lv R; Cui T; Hogan RE; Wang Q
    J Neuroimmunol; 2022 Dec; 373():578000. PubMed ID: 36410057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CSF-Neurofilament Light Chain Levels in NMDAR and LGI1 Encephalitis: A National Cohort Study.
    Nissen MS; Ryding M; Nilsson AC; Madsen JS; Olsen DA; Halekoh U; Lydolph M; Illes Z; Blaabjerg M
    Front Immunol; 2021; 12():719432. PubMed ID: 34975832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autoimmune parkinsonism with faciobrachiocrural dystonic seizures: a new phenotype of leucine-rich glioma-inactivated 1 (LGI1) autoimmunity.
    Sasikumar S; Vincent J; Gopinath S; Nambiar V; Umesh SU; Kannoth S; Antony D; Mathai A; Anandakuttan A
    Acta Neurol Belg; 2022 Oct; 122(5):1323-1328. PubMed ID: 35851655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differentially expressed microRNAs in peripheral blood mononuclear cells of non-segmental vitiligo and their clinical significance.
    Zhang Z; Yang X; Liu O; Cao X; Tong J; Xie T; Zhang J; Peng Y
    J Clin Lab Anal; 2021 Feb; 35(2):e23648. PubMed ID: 33169883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term evolution and prognostic factors of epilepsy in limbic encephalitis with LGI1 antibodies.
    Guery D; Cousyn L; Navarro V; Picard G; Rogemond V; Bani-Sadr A; Shor N; Joubert B; Muñiz-Castrillo S; Honnorat J; Rheims S
    J Neurol; 2022 Sep; 269(9):5061-5069. PubMed ID: 35595970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Case Report: Paroxysmal weakness of unilateral limb as an initial symptom in anti-LGI1 encephalitis: a report of five cases.
    Wang S; Wang J; Li B; Hu N; Jin Y; Han S; Shang X
    Front Immunol; 2023; 14():1191823. PubMed ID: 37304289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sleep Disorders in Leucine-Rich Glioma-Inactivated Protein 1 and Contactin Protein-Like 2 Antibody-Associated Diseases.
    Lin N; Hao H; Guan H; Sun H; Liu Q; Lu Q; Jin L; Ren H; Huang Y
    Front Neurol; 2020; 11():696. PubMed ID: 32849186
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical Characteristics of Cognitive Impairment and 1-Year Outcome in Patients With Anti-LGI1 Antibody Encephalitis.
    Hang HL; Zhang JH; Chen DW; Lu J; Shi JP
    Front Neurol; 2020; 11():852. PubMed ID: 33162923
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.